ArticleFrontiers in psychiatry2025
Optimizing the diagnosis and treatment of depression in primary care: the emerging role of vortioxetine treatment.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The METOD study: exploring metabolism, emotional blunting and treatment outcomes in depression - A naturalistic, two-phase observational protocol.Frontiers in pharmacology · 2026Article
- Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus: a dose-dependent recurrence confirmed on rechallenge and managed with vortioxetine-bupropion combination therapy.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of patients with major depressive disorder (MDD) in primary care (PC) represents a significant challenge and a great opportunity for early and effective intervention. Primary care physicians, as first-line physicians, play a key role in the identification, diagnosis and initial treatment of depression, often being the first and sometimes the only point of contact for these patients with the healthcare system. In this context, the search for effective and well-tolerated therapeutic strategies is constant, and vortioxetine represents a good pharmacological option within the therapeutic armamentarium available to the PC physician. This article explores best practices in the management of MDD from the PC perspective, addressing the specific challenges faced by these professionals and examining the potential role of vortioxetine in the treatment of different patient profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.